Breaking News

Krystal Biotech Completes GMP Facility

The 4,500 sq ft facility, named Ancoris, will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for the treatment of DEB

Krystal Biotech Inc. announced that construction of Ancoris, a new state-of-the-art GMP facility, is complete.    The new facility is located near the Company’s headquarters in Pittsburgh and will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). The facility will be officially open in 1Q 2019 following completion of the first engineering run. “Our development of internal manufactu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters